BioCryst Taps Sandeep Menon to Drive navenibart BLA, Astria Integration
BioCryst appoints Sandeep Menon as Chief R&D Officer, leveraging his leadership at Alnylam and Pfizer to advance its commercial pipeline anchored by ORLADEYO and the navenibart program acquired via Astria. Menon’s track record—securing FDA approval of AMVUTTRA and co-leading PAXLOVID development—aims to sharpen R&D strategy and value creation.
1. Appointment Details
BioCryst has named Sandeep M. Menon, MD, PhD, as Chief Research and Development Officer. He will oversee global clinical development, safety and regulatory strategy for the company’s rare disease programs, reporting directly to CEO Charlie Gayer.
2. Strategic R&D Focus
Menon joins as BioCryst leverages ORLADEYO’s commercial momentum and integrates Astria Therapeutics assets, including navenibart, which is advancing toward a potential BLA. His role will prioritize disciplined drug development, capital allocation and regulatory delivery for innovative therapies.
3. Menon's Track Record
At Alnylam, Menon led the team that read out and secured FDA approval of AMVUTTRA (vutrisiran) for ATTR cardiomyopathy, and at Pfizer he co-led PAXLOVID’s rapid development to emergency use authorization. He also advanced multiple oncology, immunology and rare disease programs through key clinical milestones.
4. Stock Impact and Outlook
The appointment underscores BioCryst’s commitment to sharpen its R&D execution and balance risk across its pipeline. Successful progression of the navenibart BLA and future rare disease launches could drive long-term value creation and influence investor sentiment.